RxDoctor Payments Data

Matthew McEwan, DO

Interventional Pain Medicine · Lakewood, WANPI 1699114025

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,094 of the $1,392 with a category attached, or 78.6%. 10 manufacturers reported payments, led by Boston Scientific at 36.2% of the total. Reporting peaked in 2023 at $441 and has fallen 82.3% since, to $78 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in WA, where the typical reported total is $2,704.

$1,392in general payments, 2019–2025

Across 33 payments — averaging $42.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$504
  • Medtronic$257
  • Nevro Corp.$232
  • Abbott$165
  • Amgen$75
  • Acera Surgical, Inc.$52
  • plus $108 from 4 others

What the payments were for

  • Grants$29821%
  • Food & beverage$1,09479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,392 in reported general payments places this provider in the 35th percentile of 30 interventional pain medicine providers in Washington.

See all interventional pain medicine providers in Washington

Medicare billing

Part B allowed, 2024
$194,768
Medicare patients
280
Services billed
3,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen223$5,870
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen187$3,846
Oxycodone Hcl218$3,205
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl16$2,669
Morphine Sulfate ErMorphine Sulfate68$1,489
Tramadol Hcl120$1,211
Gabapentin78$1,006
Pregabalin56$653
Cyclobenzaprine Hcl31$457
Methocarbamol13$396
Baclofen31$246
Tizanidine Hcl28$174
Diazepam14$18

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Lakewood

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →